Transformative Diagnostics



bioref


Next-Generation Therapies & Vaccines

Addressing large, unmet global markets with innovative proprietary products More »

Worldwide Production & Distribution

Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »

Strategic Investments

Identifying early-stage companies with potential to increase value for shareholders More »

Chairman’s Message

OPKO continues to make progress with its program to build a company capable of long-term growth and increasing value to its investors and I would like to review several highlights.

 

  

 OPKO Completes Acquisition of Bio-Reference Laboratories.

 

 

OPKO Letter to Shareholders»

News & Events

more news »

OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy more »

OPKO Health Reports 2017 Third Quarter Highlights and Financial Results more »

OPKO Health to Announce 2017 Third Quarter Financial Results on November 8, 2017 more »

Investors

read more »

OPKO Health is an opportunistic research and development company that targets large, high-growth markets.

 

 

FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »